| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
PARP10 (ARTD10) and OGG1 (8-oxoguanine DNA glycosylase 1). OUL35 is a selective PARP-10 inhibitor with an IC50 of 329 nM. It is selective for PARP10 over a panel of 15 PARP enzymes, including PARP4, PARP14, and PARP16. PARP10 (ARTD10) is a mono-ADP-ribosyltransferase that plays a role in DNA repair, cell signaling, and apoptosis. By inhibiting PARP10, OUL35 rescues cells from ARTD10-induced cell death. OUL35 is also described as a selective small-molecule inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1). OGG1 is a key enzyme in the base excision repair (BER) pathway responsible for removing oxidative DNA lesions, particularly 8-oxoguanine. By blocking OGG1 activity, OUL35 modulates DNA damage repair, influencing genomic stability, transcriptional regulation, and inflammatory responses.
|
|---|---|
| ln Vitro |
OuL35 purifies cells sensitive to combined DNA damage and saves HeLa cells from ARTD10-induced cell death. OuL35 (3 μM) in U2OS cells and endogenous ARTD10 [1]. ARTD8 (23.4 μM), ARTD4 (22.6 μM), and ARTD15 (4.17 μM) are also moderately inhibited by OuL35 [1]. OuL35 establishes hydrogen bonds with Gly888's amide and lacquer groups as well as Ser927's side chain support. In the crystal structure, the OuL35 moiety relays 3AB and is located between Tyr919 and Tyr932 [1].
OUL35 demonstrates potent inhibition of PARP10 with an IC50 of 329 nM. It is selective for PARP10 over a panel of 15 PARP enzymes. The compound rescues HeLa cells from ARTD10-induced apoptotic cell death. As an OGG1 inhibitor, OUL35 blocks OGG1 activity, modulating DNA damage repair. OUL35 is used in chemical biology and pharmacology research to study the role of OGG1 in oxidative stress-related diseases, cancer, and inflammation. The compound's cell-permeable nature allows it to effectively inhibit its targets in intact cells. |
| ln Vivo |
OUL35 has been studied in vivo for its effects on DNA repair and cell survival. The compound rescues cells from ARTD10-induced cell death. As an OGG1 inhibitor, it modulates DNA damage repair, influencing genomic stability and inflammatory responses. OUL35 has been shown to sensitize cancer cells to DNA damage. Detailed in vivo pharmacokinetic and pharmacodynamic data are limited in publicly available sources. OUL35 is for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
PARP10 enzyme activity assays are performed using recombinant PARP10 enzyme and a substrate such as biotinylated NAD+. The enzyme is incubated with the substrate in assay buffer (50 mM Tris-HCl pH 8.0, 10 mM MgCl₂, 1 mM DTT) at room temperature for 30-60 minutes. PARP10 activity is measured by the incorporation of labeled NAD+ into acceptor proteins. OUL35 is serially diluted in DMSO and added to the reaction mixture. The IC50 for PARP10 inhibition is 329 nM. Each concentration is tested in duplicate, and IC50 values are calculated by non-linear regression analysis. Appropriate positive controls and vehicle controls are included to validate the assay.
|
| Cell Assay |
Cellular PARP10 and OGG1 inhibition is evaluated in HeLa cells or other cell lines. Cells are cultured in appropriate media at 37°C with 5% CO₂ and treated with OUL35 at various concentrations for 24-72 hours. PARP10 activity in cell lysates is assessed by measuring mono-ADP-ribosylation. Cell viability is assessed using MTT or CellTiter-Glo assays to evaluate rescue from ARTD10-induced apoptosis. DNA damage repair is assessed by measuring oxidative DNA lesions or by using reporter assays. Each experiment includes vehicle controls and appropriate positive controls to validate the assay systems.
|
| Animal Protocol |
In vivo efficacy of OUL35 is evaluated in animal models of cancer and inflammation. The compound is administered orally or intraperitoneally at doses determined by preclinical studies. Tumor growth is monitored in xenograft models. The compound's ability to sensitize cancer cells to DNA damage is assessed. Inflammatory markers are measured in models of inflammation. Tissue samples are collected for histopathological analysis and biochemical assays (PARP10 activity, OGG1 activity, DNA damage markers). Body weight and clinical signs are monitored throughout the study to assess tolerability. Sample sizes typically range from 6-10 animals per group.
|
| ADME/Pharmacokinetics |
Molecular Weight: 256.26. Formula: C14H12N2O3. CAS No.: 6336-34-1. IUPAC Name: 4,4'-oxydibenzamide. Synonyms: NSC39047, 4-(4-carbamoylphenoxy)benzamide. Appearance: Solid. Purity: ≥95-98%. Solubility: DMSO: 20 mg/mL. Storage: Powder at -20°C for 3 years; 4°C for 2 years. OUL35 is a selective PARP10 inhibitor with an IC50 of 329 nM.
|
| Toxicity/Toxicokinetics |
No comprehensive toxicology data are publicly available for OUL35. The compound is intended for research use only and has not undergone full preclinical toxicology evaluation required for clinical development. As a PARP10 and OGG1 inhibitor, potential toxicities may include effects on DNA repair and cell survival. Standard toxicity studies would include acute toxicity assessment in rodents, repeated dose toxicity studies (14-day and 28-day), and genotoxicity screening (Ames test, micronucleus assay). The compound is for research use only and not for human therapeutic use.
|
| References | |
| Additional Infomation |
OUL35 is also known as NSC39047, 4-(4-carbamoylphenoxy)benzamide. Its IUPAC name is 4,4'-oxydibenzamide. OUL35 is a selective PARP10 inhibitor with an IC50 of 329 nM. It rescues cells from ARTD10-induced cell death. OUL35 is also an OGG1 inhibitor that modulates DNA damage repair. No clinical trials have been reported for this compound. OUL35 is for research use only.
|
| Molecular Formula |
C14H12N2O3
|
|---|---|
| Molecular Weight |
256.261
|
| Exact Mass |
256.085
|
| Elemental Analysis |
C, 65.62; H, 4.72; N, 10.93; O, 18.73
|
| CAS # |
6336-34-1
|
| PubChem CID |
236501
|
| Appearance |
White to off-white solid powder
|
| Density |
1.298g/cm3
|
| Boiling Point |
488.8ºC at 760 mmHg
|
| Flash Point |
257.9ºC
|
| Index of Refraction |
1.633
|
| LogP |
3.077
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
298
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C(=O)N)OC2=CC=C(C=C2)C(=O)N
|
| InChi Key |
XZRCQWLPMXFGHE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12N2O3/c15-13(17)9-1-5-11(6-2-9)19-12-7-3-10(4-8-12)14(16)18/h1-8H,(H2,15,17)(H2,16,18)
|
| Chemical Name |
4-(4-carbamoylphenoxy)benzamide
|
| Synonyms |
OUL-35 OUL 35 OUL35
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~325.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9023 mL | 19.5114 mL | 39.0229 mL | |
| 5 mM | 0.7805 mL | 3.9023 mL | 7.8046 mL | |
| 10 mM | 0.3902 mL | 1.9511 mL | 3.9023 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
